Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer

Gheorghe, Andreea-Daniela; Zob, Daniela; Stanculeanu, Dana-Lucia

Andreea-Daniela Gheorghe, Daniela Zob, Dana-Lucia Stanculeanu

Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer

Abstract:

Even with the decreasing incidence of colorectal cancer (CRC), data showing that the rate of incidence of CRC is declining with 2.9% every year starting with 2005 until 2014, CRC remains one of the most frequent neoplasia all over the world. Almost a quarter of patients with CRC present with stage IV disease at diagnosis and nearly 30% of patients with localized disease will progress within 5 years. Our study included 129 patients with metastatic CRC that received chemotherapy ± bevacizumab, from January 2017 until December 2018. Patients received fluropirimidine-based chemotherapy plus or minus bevacizumab. No significant differences was registered between groups with respects of age, sex, tumor localization, chemotherapy regimen used. Also no significant difference was found in our groups regarding risk factors for bleeding and medical history. No remarkable differences were registered between the two groups regarding common adverse reactions to chemotherapy, with the exception of physical asthenia which was found in a greater proportion of patients that received bevacizumab in combination with chemotherapy. In our study most frequent adverse events related to bevacizumab were grade 1 or 2, only few adverse events were grade 3 or 4 and lead to discontinuation of bevacizumab treatment, and these were mainly thromboembolic events and bleeding.

Keywords:
metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events

Issue: 2020, Volume 71, Issue 1

Pages: 140-144

Publication date: 2020/2/7

https://doi.org/10.37358/RC.20.1.7824

Download Pdf Article

This article is published under the Creative Commons Attribution 4.0 International License

Citation Styles

Cite this article as:
GHEORGHE, A., ZOB, D., STANCULEANU, D., Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer, Rev. Chim., 71(1), 2020, 140-144.

Vancouver
Gheorghe A, Zob D, Stanculeanu D. Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Rev. Chim.[internet]. 2020 Jan;71(1):140-144. Available from: https://doi.org/10.37358/RC.20.1.7824

APA 6th edition
Gheorghe, A., Zob, D. & Stanculeanu, D. (2020). Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Revista de Chimie, 71(1), 140-144. https://doi.org/10.37358/RC.20.1.7824

Harvard
Gheorghe, A., Zob, D., Stanculeanu, D. (2020). 'Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer', Revista de Chimie, 71(1), pp. 140-144. https://doi.org/10.37358/RC.20.1.7824

IEEE
A. Gheorghe, D. Zob, D. Stanculeanu, "Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer". Revista de Chimie, vol. 71, no. 1, pp. 140-144, 2020. [online]. https://doi.org/10.37358/RC.20.1.7824

Text
Andreea-Daniela Gheorghe, Daniela Zob, Dana-Lucia Stanculeanu,
Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer,
Revista de Chimie,
Volume 71, Issue 1,
2020,
Pages 140-144,
ISSN 2668-8212,
https://doi.org/10.37358/RC.20.1.7824.
(https://revistadechimie.ro/Articles.asp?ID=7824)
Keywords: metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events

RIS
TY - JOUR
T1 - Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer
A1 - Gheorghe, Andreea-Daniela
A2 - Zob, Daniela
A3 - Stanculeanu, Dana-Lucia
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2020
VL - 71
IS - 1
SP - 140
EP - 144
UR - https://doi.org/10.37358/RC.20.1.7824
KW - metastatic colorectal cancer
KW - bevacizumab
KW - chemotherapy
KW - adverse events
ER -

BibTex
@article{RevCh2020P140,
author = {Gheorghe Andreea-Daniela and Zob Daniela and Stanculeanu Dana-Lucia},
title = {Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer},
journal = {Revista de Chimie},
volume = {71},
number = {1},
pages = {140-144},
year = {2020},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.20.1.7824},
url = {https://revistadechimie.ro/Articles.asp?ID=7824}
}

<<<< back

PUBLISHING SECTION

Author Guidelines

* Paper Drafting

* Paper Template

* Ethical Statement

* Paper Submission

Ghidul Autorului (ro)